Compare QUALCOMM, Inc. (QCOM) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
QUALCOMM, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? QUALCOMM, Inc. trades at $176.73 (market cap $182.87B), while State Street SPDR S&P Biotech ETF trades at $151.92. The key difference: QUALCOMM, Inc. pays a 2.12% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, QUALCOMM, Inc. nearer its low. Which is the better fit depends on your goals.
| QCOM | XBI | |
|---|---|---|
Market Cap | $182.87B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $251.10 | $164.28 |
52-Week Low | $124.07 | $85.16 |
Enterprise Value | $188.34B | — |
Dividend Yield | 2.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Qualcomm (QCOM) trades at $170.32, down 0.85% with bearish technical signals despite recent earnings beats. The stock shows strong fundamentals with 22.31% net margins and 29.27% ROE, though facing margin pressures and smartphone market headwinds. Recent news highlights AI diversification efforts through automotive and data center markets, with CEO Cristiano Amon projecting 'multiple billions' in data center revenue ahead.
Outlook remains mixed with 42.65% analyst buy ratings and $228.22 consensus target suggesting 34% upside, but technical weakness and competitive threats from Nvidia's PC chip entry create near-term uncertainty. Key risks include smartphone demand softness and margin compression, while AI expansion provides long-term growth potential.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
